Hot topics
Statins and PCSK9 inhibitors in combination: Initial therapy in very high-risk patients in secondary prevention
Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board Alberto Zambon
read more »
Elevated LDL-C and elevated Lp(a) with recurrent MACE: What to do, to do what?
Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board Erik Stroes
read more »
Aortic valve stenosis: A key pathophysiological role for Lp(a)?
Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board Benoit Arsenault
read more »
Lp(a) and plaque progression: Insights from imaging
Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board Marc Dweck
read more »
LDL-C lowering with PCSK9 inhibition: Multi-modal imaging and impact on coronary plaque in ACS patients
Reports from the 18th Virtual Closed Scientific Expert Meeting of the Editorial Board Stephen Nicholls
read more »
siRNA-mediated lowering of Lp(a) by Olpasiran
Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board Michael Koren
read more »
A new ASO PCSK9 inhibitor: The Etesian study
Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board Alexis Hofherr
read more »
ASO-mediated reduction in Lp(a) levels: Update on Pelacarsen
Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board Sotirios Tsimikas
read more »
siRNA-mediated lowering of Lp(a) by SLN360
Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board Steve Nissen
read more »
PCSK9 and diabetes risk
Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board Wilfried Le Goff
read more »
Keynote: Clinical utility of cIMT in determining management of children with heFH and of CTCA in determining treatment effects in children with hoFH
Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board Albert Wiegman
read more »
How much reduction of Lp(a) is needed to translate into major clinical benefit? Setting the scene: Focus on PCSK9 inhibitors
Reports from the 17th Virtual Closed Scientific Expert Meeting of the Editorial Board Pia Kamstrup
read more »
Keynote: PCSK9 gene variants – An update
Reports from the 16th Virtual Closed Scientific Expert Meeting of the Editorial Board Marianne Abi-Fadel
read more »
PCSK9 inhibitors in type 2 diabetes: New insights from clinical trials and epidemiologic and genetic data
Reports from the 16th Virtual Closed Scientific Expert Meeting of the Editorial Board Lawrence Leiter
read more »
Keynote – History of PCSK9
Reports from the 15th Virtual Closed Scientific Expert Meeting of the Editorial Board Professor Nabil Seidah
read more »
Keynote – How does LDL lowering stabilize vulnerable plaques?
Reports from the 15th Virtual Closed Scientific Expert Meeting of the Editorial Board Professor Peter Libby
read more »
Is a ‘once-and-done’ approach to LDL lowering feasible?
Reports from the 15th Virtual Closed Scientific Expert Meeting of the Editorial Board Professor Kiran Musunuru
read more »
Where next for cost-effectiveness analysis of combination LDL lowering therapies?
Reports from the 15th Virtual Closed Scientific Expert Meeting of the Editorial Board Professor Dhruv Kazi
read more »
Low lipoprotein(a): Is there any potential risk?
Reports from the 14th Virtual Closed Scientific Expert Meeting of the Editorial Board Dr Anne Langsted
read more »
Cholesterol crystals, plaque stability and ASCVD
Reports from the 14th Virtual Closed Scientific Expert Meeting of the Editorial Board Professor John Chapman
read more »
